Publication: 4702

Publication: 4702

Short TeRm Intensified Pembrolizumab (KEytrude) and Tivozanib for Hogh-Risk Renal Cell Carcinoma – STRIKE! (Alliance A032201)

DOI

URL

Google Scholar

Citation:: The Oncologist vol 30 (Supplement_2) oyaf276.022

Meeting Instance:: KCRS 2025
Year:: 2025
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: No-Endpoint
Analysis:: Trial-Description-Only
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:: AVEO Pharmaceuticals, Inc.;
Grants:: U10CA180821, U10CA180882; U10CA180868 (NRG Oncology);

Corr. Author:
Authors:: Bradley McGregor Karla Ballman Gabriela Perez Alan Tan Stephanie Berg Tian Zhang Ronald Chen Matt Galsky Jonathan Rosenberg Daniel George

Networks:: KANSAS, LAPS-MA036, LAPS-NC010, LAPS-NY016, LAPS-TN008, LAPS-TX011

Study: Alliance-A032201
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: